Type 1 diabetes

Dr. An Chiying and type 1 diabetes: what the reports mean for you

Read that Dr. An Chiying's team helped people with type 1 diabetes stop insulin? What that means, what is proven, and what to ask before you travel.

Written by the International Medical Center editorial teamReviewed by Adam Lam, Health Manager, Dr. An Chiying's endocrinology team, Shenzhen Hengsheng HospitalUpdated 30 Oct 20267 sources
Short answer: News reports have described Dr. An Chiying's team at Shenzhen Hengsheng Hospital helping some people with type 1 diabetes manage without insulin [1]. These are the team's own clinical reports and have not yet been published as a peer-reviewed study. Type 1 diabetes usually needs insulin for life, so the useful question is what your own test results show, and only your physician should ever change your insulin.

What has been reported about Dr. An Chiying's type 1 work?

Since 2025, press releases and news stories have described Dr. An Chiying's endocrinology team using an integrative approach, combining functional-medicine testing, nutrition and lifestyle care, with people who have type 1 diabetes [1]. Some of those reports use phrases such as "functional remission" or "functional cure".

We do not repeat outcome figures on this site. The results have not been published in a peer-reviewed journal, so nobody outside the team has checked them, and a figure from a group of other patients tells you little about your own chances. What we can tell you is how the team assesses type 1 diabetes and what the wider evidence says.

Why type 1 diabetes is different

In type 1 diabetes the immune system destroys the cells in the pancreas that make insulin, which usually leads to a lasting lack of insulin [2]. That is different from type 2 diabetes, where the body still makes insulin but cannot use it well, and where remission is a recognized possibility for some people.

The amount of insulin your own body still makes can be measured with a C-peptide test. C-peptide is released in equal amounts to insulin, so it is the best measure of your own insulin production [3]. An absent C-peptide confirms that insulin treatment is essential [3].

What is the "honeymoon" phase?

Soon after diagnosis, many people with type 1 diabetes go through a period when their remaining insulin-making cells recover a little and their insulin needs fall. Doctors call this partial remission, or the honeymoon phase. One widely used definition, from a study of children and adolescents, combines HbA1c with the daily insulin dose: partial remission is when HbA1c (%) plus four times the insulin dose (units per kg per day) is 9 or lower [4].

The honeymoon phase is temporary for most people. A fall in insulin needs during this time is real, but it does not mean the underlying condition has gone.

Can anyone with type 1 diabetes live without insulin?

Research is moving. In a 2025 trial of stem-cell-derived islet cells, 10 of 12 people who received the full dose were not using insulin one year later, but every participant needed long-term immune-suppressing medicine and the authors describe the study as small and short-term [5]. A 2024 report from China described one patient who no longer needed insulin after a transplant of islets grown from her own reprogrammed stem cells [6]. These are research treatments in specialist trials, not routine care.

Never stop insulin on your own

Stopping insulin in type 1 diabetes can lead to diabetic ketoacidosis, a life-threatening emergency [7]. Any change to your insulin must be decided by your physician, based on your readings, and made step by step under supervision. This applies to every program, including ours.

What Dr. An Chiying's team does for type 1 diabetes

People with type 1 diabetes can be assessed by the team. The assessment in Shenzhen takes about ten days and includes C-peptide and insulin testing. The physician then sets an individual plan and cost with you, built around your own results, with the aim of steadier blood sugar. The assessment costs CNY 10,000–20,000 depending on the test panel; the type 1 plan is quoted after it.

If you have type 1 diabetes and are thinking about the trip, send your latest HbA1c, C-peptide result and insulin doses for a free case review. The team will tell you honestly whether the assessment is likely to help.

Questions

Frequently asked

Has Dr. An Chiying's team published its type 1 results?

The team's type 1 results have been described in press releases and news reports. At the time of writing they have not been published as a peer-reviewed study, so there are no independently checked figures to quote. If you are considering the program, ask the team what your own C-peptide and insulin results suggest for you.

Can people with type 1 diabetes stop insulin?

For almost everyone with type 1 diabetes, insulin is lifelong treatment. Some people need much less insulin for a while soon after diagnosis, which is called partial remission or the honeymoon phase. Living without insulin has been seen in small research studies of stem-cell islet transplants, which need long-term immune-suppressing medicine. Never stop insulin without your physician.

What is a C-peptide test and why does it matter?

C-peptide is released in the same amount as the insulin your own pancreas makes, so it shows how much insulin you still produce. In type 1 diabetes this is usually low and falls over time. Dr. An Chiying's team uses C-peptide and insulin results from the assessment to decide what a realistic plan for you looks like.

How do I contact Dr. An Chiying's team?

International patients reach the team through the International Medical Center of Shenzhen Hengsheng Hospital. Send your latest reports on WhatsApp to Ryan Guo at (+86) 130-5800-1181 for a free case review, or start from the Diabetes Program page. The official channels are listed on Dr. An Chiying's profile page.

Sources

References

  1. Bernama press release, August 2025: type 1 diabetes treatment by a Chinese medical team (Shenzhen Hengsheng Hospital) www.bernama.com/en/press/news.php?id=2458940
  2. American Diabetes Association. 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2025. Diabetes Care 2025;48(Suppl 1):S27–S49 doi.org/10.2337/dc25-S002
  3. Jones AG, Hattersley AT. The clinical utility of C-peptide measurement in the care of patients with diabetes. Diabet Med 2013;30(7):803–817 pubmed.ncbi.nlm.nih.gov/23413806/
  4. Mortensen HB, et al. New definition for the partial remission period in children and adolescents with type 1 diabetes. Diabetes Care 2009;32(8):1384–1390 pubmed.ncbi.nlm.nih.gov/19435955/
  5. Reichman TW, et al. Stem Cell–Derived, Fully Differentiated Islets for Type 1 Diabetes. N Engl J Med 2025 pubmed.ncbi.nlm.nih.gov/40544428/
  6. Wang S, et al. Transplantation of chemically induced pluripotent stem-cell-derived islets under abdominal anterior rectus sheath in a type 1 diabetes patient. Cell 2024 pubmed.ncbi.nlm.nih.gov/39326417/
  7. Umpierrez GE, et al. Hyperglycemic Crises in Adults With Diabetes: A Consensus Report. Diabetes Care 2024 pubmed.ncbi.nlm.nih.gov/39052901/

This article is general information, not medical advice. Do not start, stop or change any medicine without your physician. Written by the editorial team of the International Medical Center (国际医疗中心) at Shenzhen Hengsheng Hospital, a National Grade-III comprehensive hospital and member of Fosun Health.